Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights